Loading...

Virbac

DB:V16
Snowflake Description

Reasonable growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
V16
DB
€1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Virbac SA produces and sells medicines and vaccines for companion and food-producing animals. The last earnings update was 35 days ago. More info.


Add to Portfolio Compare Print
  • Virbac has significant price volatility in the past 3 months.
V16 Share Price and Events
7 Day Returns
-5.3%
DB:V16
-0.6%
DE Pharmaceuticals
1.8%
DE Market
1 Year Returns
18.5%
DB:V16
-21.5%
DE Pharmaceuticals
-6%
DE Market
V16 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Virbac (V16) -5.3% 11.9% 33.6% 18.5% -7.7% -9.8%
DE Pharmaceuticals -0.6% 0.2% -1.4% -21.5% -26.2% 8.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • V16 outperformed the Pharmaceuticals industry which returned -21.5% over the past year.
  • V16 outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
V16
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Virbac undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Virbac to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Virbac.

DB:V16 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:V16
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6.7%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.729 (1 + (1- 33%) (37.86%))
0.942
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.94
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.942 * 6.65%)
6.49%

Discounted Cash Flow Calculation for DB:V16 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Virbac is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:V16 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 6.49%)
2019 38.40 Analyst x2 36.06
2020 57.36 Analyst x5 50.58
2021 70.63 Analyst x4 58.48
2022 95.90 Analyst x1 74.57
2023 110.00 Analyst x1 80.31
2024 120.63 Est @ 9.66% 82.71
2025 128.87 Est @ 6.83% 82.97
2026 135.12 Est @ 4.85% 81.69
2027 139.80 Est @ 3.46% 79.37
2028 143.29 Est @ 2.49% 76.39
Present value of next 10 years cash flows €703.11
DB:V16 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €143.29 × (1 + 0.23%) ÷ (6.49% – 0.23%)
€2,292.45
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €2,292.45 ÷ (1 + 6.49%)10
€1,222.10
DB:V16 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €703.11 + €1,222.10
€1,925.21
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €1,925.21 / 8.43
€228.38
DB:V16 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:V16 represents 0.99739x of ENXTPA:VIRP
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.99739x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 228.38 x 0.99739
€227.78
Value per share (EUR) From above. €227.78
Current discount Discount to share price of €152.60
= -1 x (€152.60 - €227.78) / €227.78
33%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Virbac is available for.
Intrinsic value
33%
Share price is €152.6 vs Future cash flow value of €227.78
Current Discount Checks
For Virbac to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Virbac's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Virbac's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Virbac's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Virbac's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:V16 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €2.39
ENXTPA:VIRP Share Price ** ENXTPA (2019-04-18) in EUR €153
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 26.82x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Virbac.

DB:V16 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:VIRP Share Price ÷ EPS (both in EUR)

= 153 ÷ 2.39

64.11x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Virbac is overvalued based on earnings compared to the DE Pharmaceuticals industry average.
  • Virbac is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Virbac's expected growth come at a high price?
Raw Data
DB:V16 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 64.11x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
25.7%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.78x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

DB:V16 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 64.11x ÷ 25.7%

2.49x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Virbac is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Virbac's assets?
Raw Data
DB:V16 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €54.65
ENXTPA:VIRP Share Price * ENXTPA (2019-04-18) in EUR €153
Germany Pharmaceuticals Industry PB Ratio Median Figure of 9 Publicly-Listed Pharmaceuticals Companies 2.39x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:V16 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:VIRP Share Price ÷ Book Value per Share (both in EUR)

= 153 ÷ 54.65

2.8x

* Primary Listing of Virbac.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Virbac is overvalued based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess Virbac's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Virbac has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Virbac expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
25.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Virbac expected to grow at an attractive rate?
  • Virbac's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Virbac's earnings growth is expected to exceed the Germany market average.
  • Virbac's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:V16 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:V16 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 25.7%
DB:V16 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 5.2%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 19.7%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 4.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:V16 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:V16 Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,135 107 1
2022-12-31 1,076 92 1
2021-12-31 1,019 137 70 4
2020-12-31 967 122 58 5
2019-12-31 925 78 46 2
DB:V16 Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 869 84 20
2018-09-30 862 93 8
2018-06-30 854 103 -4
2018-03-31 858 105 -3
2017-12-31 862 108 -3
2017-09-30 871 112 16
2017-06-30 879 117 35
2017-03-31 876 130 35
2016-12-31 872 142 35
2016-09-30 861 119 30
2016-06-30 850 95 26
2016-03-31 851 71 18

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Virbac's earnings are expected to grow significantly at over 20% yearly.
  • Virbac's revenue is expected to grow by 5.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:V16 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Virbac Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:V16 Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 12.74 12.74 12.74 1.00
2022-12-31 10.94 10.94 10.94 1.00
2021-12-31 8.11 9.27 6.99 4.00
2020-12-31 6.87 7.71 6.38 5.00
2019-12-31 5.42 5.52 5.32 2.00
DB:V16 Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 2.39
2018-09-30 0.94
2018-06-30 -0.50
2018-03-31 -0.40
2017-12-31 -0.31
2017-09-30 1.95
2017-06-30 4.21
2017-03-31 4.16
2016-12-31 4.11
2016-09-30 3.62
2016-06-30 3.12
2016-03-31 2.12

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Virbac is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Virbac's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Virbac has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Virbac performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Virbac's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Virbac's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Virbac has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Virbac has become profitable in the last year making it difficult to compare the DE Pharmaceuticals industry average.
Earnings and Revenue History
Virbac's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Virbac Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:V16 Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 868.93 20.10 446.32
2018-09-30 861.62 7.94 441.99
2018-06-30 854.31 -4.23 437.66
2018-03-31 858.09 -3.40 439.90
2017-12-31 861.88 -2.58 442.15
2017-09-30 870.64 16.45 444.14
2017-06-30 879.40 35.47 446.14
2017-03-31 875.62 35.06 448.89
2016-12-31 871.83 34.65 451.64
2016-09-30 861.07 30.49 458.84
2016-06-30 850.30 26.33 466.04
2016-03-31 851.46 17.87 463.18
2015-12-31 852.62 9.41 460.32
2015-09-30 845.84 20.68 440.85
2015-06-30 839.06 31.95 421.37
2015-03-31 806.09 47.78 398.43
2014-12-31 773.12 63.60 375.50
2014-09-30 751.78 59.67 366.16
2014-06-30 730.44 55.74 356.82
2014-03-31 733.26 58.13 356.13
2013-12-31 736.08 60.52 355.45
2013-09-30 726.89 60.91 355.63
2013-06-30 717.69 61.30 355.81
2013-03-31 706.42 63.96 350.08
2012-12-31 695.16 66.63 344.35
2012-09-30 676.56 64.74 334.45
2012-06-30 657.97 62.85 324.55

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Virbac has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Virbac used its assets less efficiently than the DE Pharmaceuticals industry average last year based on Return on Assets.
  • Virbac has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Virbac's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Virbac has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Virbac's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Virbac's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Virbac is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Virbac's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Virbac's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Virbac Company Filings, last reported 3 months ago.

DB:V16 Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 495.87 488.36 63.55
2018-09-30 495.87 488.36 63.55
2018-06-30 486.63 542.22 55.94
2018-03-31 486.63 542.22 55.94
2017-12-31 478.82 508.12 49.72
2017-09-30 478.82 508.12 49.72
2017-06-30 511.15 589.64 46.95
2017-03-31 511.15 589.64 46.95
2016-12-31 520.79 593.17 48.45
2016-09-30 520.79 593.17 48.45
2016-06-30 488.96 666.85 60.23
2016-03-31 488.96 666.85 60.23
2015-12-31 482.29 656.74 51.16
2015-09-30 482.29 656.74 51.16
2015-06-30 478.05 682.89 50.72
2015-03-31 478.05 682.89 50.72
2014-12-31 482.19 574.85 375.91
2014-09-30 482.19 574.85 375.91
2014-06-30 424.68 307.83 43.72
2014-03-31 424.68 307.83 43.72
2013-12-31 414.37 215.61 35.71
2013-09-30 414.37 215.61 35.71
2013-06-30 404.93 246.94 32.84
2013-03-31 404.93 246.94 32.84
2012-12-31 398.42 173.13 39.75
2012-09-30 398.42 173.13 39.75
2012-06-30 339.66 137.71 53.13
  • Virbac's level of debt (98.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (52.3% vs 98.5% today).
  • Debt is not well covered by operating cash flow (17.1%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 4.5x coverage).
X
Financial health checks
We assess Virbac's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Virbac has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Virbac's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Virbac dividends. Estimated to be 1.5% next year.
If you bought €2,000 of Virbac shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Virbac's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Virbac's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:V16 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 3%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:V16 Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31 3.18 1.00
2022-12-31 2.73 1.00
2021-12-31 2.43 3.00
2020-12-31 1.90 3.00
2019-12-31 1.80 1.00
DB:V16 Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2016-09-19 0.000 0.000
2016-04-22 0.000 0.000
2016-03-15 0.000 0.000
2015-04-23 1.900 0.994
2015-03-17 1.900 0.838
2014-04-30 1.900 1.094
2014-03-19 1.900 1.154
2013-04-30 1.900 1.215
2012-05-14 1.750 1.206
2012-03-13 1.750 1.446
2011-04-29 1.500 1.269
2011-01-17 1.500 1.320
2010-03-15 1.320 1.375
2009-12-31 1.320 1.808
2009-04-23 1.200 1.932

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Virbac has not reported any payouts.
  • Unable to verify if Virbac's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Virbac's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Virbac has not reported any payouts.
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3.5x coverage).
X
Income/ dividend checks
We assess Virbac's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Virbac afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Virbac has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Virbac's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Éric Marée
COMPENSATION €454,660
AGE 65
CEO Bio

Mr. Éric Marée serves as the President and Chief Executive Officer at Virbac SA and served as its Chairman of the Executive Board from December 15, 1999 to 2018 and Member of its Executive Board from 1999 to 2018. Mr. Marée joined Virbac S.A. in October 1999 and he served as the Chief Executive Officer of Laboratories Roche Nicholas and Vice President of Roche Consumer Health, two subsidiaries of Hoffman La Roche, from 1994 to 1999. Mr. Marée serves as the Chairman of Virbac Corp. He served as Chairman of Interlab (France) and Chairman of Executive Board of Virbac Corporation (USA). He has been a Director of Virbac Corp. since January 2000. He serves as a Director of Virbac (Australia) Pty Ltd (Australia), Vetsearch International Pty Ltd (Australia), MR- 067 579 122 Pty Ltd (Australia), Virbac Limited (UK), Vetsearch International (UK) Ltd (UK), Laboratorios Virbac Mexico SA de CV (Mexico), Virbac Mexico SA de CV (Mexico) and Virbac Animal Health India Private Limited (India). Mr. Marée is a member of the Board of the International Federation for Animal Health. Mr. Marée holds graduate of the HEC and an MBA from Cornell University.

CEO Compensation
  • Éric's compensation has been consistent with company performance over the past year.
  • Éric's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Virbac management team in years:

12.6
Average Tenure
52
Average Age
  • The average tenure for the Virbac management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Éric Marée

TITLE
CEO & President
COMPENSATION
€455K
AGE
65

Sébastien Huron

TITLE
Chairman of the Executive Board
COMPENSATION
€311K
AGE
47
TENURE
1.3 yrs

Habib Ramdani

TITLE
CFO & Member of Executive Board
COMPENSATION
€212K
AGE
42
TENURE
2.8 yrs

Christian Karst

TITLE
Executive VP of Corporate Development
COMPENSATION
€332K
AGE
59
TENURE
22.3 yrs

Jean-Pierre Dick

TITLE
Member of Executive Board
COMPENSATION
€42K
AGE
52
TENURE
22.3 yrs

Sandrine Brunel

TITLE
Head of Corporate Communications

Francesca Cortella

TITLE
Head of Corporate Human Resources

Marc Bistuer

TITLE
Head of Global Industrial Operations & Corporate Quality Assurance
Board of Directors Tenure

Average tenure and age of the Virbac board of directors in years:

6.8
Average Tenure
57
Average Age
  • The tenure for the Virbac board of directors is about average.
Board of Directors

Marie-Hélène Dick-Madelpuech

TITLE
Chairwoman of Supervisory Board
COMPENSATION
€116K
AGE
53
TENURE
13 yrs

Pierre Madelpuech

TITLE
Vice Chairman of Supervisory Board
COMPENSATION
€6K
AGE
57

Herve Capron

TITLE
Independent Member of the Supervisory Board
COMPENSATION
€24K
AGE
59
TENURE
15.3 yrs

Xavier Yon

TITLE
Non-Voting Member of the Supervisory Board
COMPENSATION
€21K
AGE
78
TENURE
4.8 yrs

Olivier Bohuon

TITLE
Independent Member of the Supervisory Board
COMPENSATION
€21K
AGE
59
TENURE
8.3 yrs

Grita Loebsack

TITLE
Independent Member of the Supervisory Board
COMPENSATION
€21K
AGE
46
TENURE
5.3 yrs

Solène Madelpuech

TITLE
Member of Supervisory Board
COMPENSATION
€17K
AGE
24
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Virbac's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Virbac has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Virbac SA produces and sells medicines and vaccines for companion and food-producing animals. The company offers Canigen vaccines; Clostrisan, a vaccine for the prevention of clostridiosis and botulism; Deltanil, a deltamethrin-based parasiticide for topical application; Effitix to treat tick, flea, and mosquito infestations; Epiotic, an ear cleanser; Eradia for the treatment of clostridium infections and giardiasis; and Fort Up, an injectable solution to control and treat gastro-intestinal and pulmonary parasiticides. It also provides Iverhart and Iverhart Max Soft Chew, a chewable tablets to prevent heartworm disease, as well as treat and control roundworms, hookworms, and tapeworms; Maxflor Duo/Maxflin, an antibiotic for the prevention and treatment of respiratory diseases; Milteforan, an oral treatment for canine leishmaniosis; Moxiheart, an internal parasiticide; and Multimin, a trace element injectable supplement. In addition, the company offers Nutribond to enhance dietary; Prinovox, an ectoparasiticide; Propofol, an anesthetic; Rilexine, a cephalexin-based antibiotic; Sentinel Flavor Tabs and Sentinel Spectrum, a polyvalent parasiticide tablets; Shotapen, a combination of antibiotics to treat bacterial infections; Speed Reader, a blood marker dosage analyzer; and Suprelorin, an implant to induce temporary infertility in male dogs. Further, it provides Tridectin, a parasiticide oral solution; Veterin, an antibiotic; Veterinary HPM, a petfood; and Zoletil, a multi-species general anaesthetic. Additionally, the company is involved in the production of moldings for third parties. It operates in France, rest of Europe, North America, Latin America, Asia, Pacific, and Africa and the Middle East. Virbac SA was founded in 1968 and is headquartered in Carros, France.

Details
Name: Virbac SA
V16
Exchange: DB
Founded: 1968
€1,289,783,115
8,429,955
Website: http://corporate.virbac.com
Address: Virbac SA
13e rue LID - BP 27,
cedex,
Carros,
Provence-Alpes-Côte d'Azur, 06511,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA VIRP Share Capital Euronext Paris FR EUR 02. Jan 1992
OTCPK VRBC.F Share Capital Pink Sheets LLC US USD 02. Jan 1992
DB V16 Share Capital Deutsche Boerse AG DE EUR 02. Jan 1992
LSE 0NM7 Share Capital London Stock Exchange GB EUR 02. Jan 1992
BATS-CHIXE VIRPP Share Capital BATS 'Chi-X Europe' GB EUR 02. Jan 1992
Number of employees
Current staff
Staff numbers
4,893
Virbac employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 21:36
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/03/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.